BridgeMD
New treatment option for ADPKD (autosomal Dominant Polycystic Kidney Disease)
Official title Shared Decision Making for Choosing Autosomal DOminant Polycystic Kidney Disease Treatment
ClinicalTrials.gov ID: NCT06618638
What this study is testing
- What it's testing
- The purpose of this study is to generate clinical evidence and assess the feasibility of a shared decision-making (SDM) model for the selection of Tolvaptan in patients with ADPKD.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Participants between the age of 18 to 80
- Participants with a diagnosis with CKD stage 2 or 3
- Participants with a diagnosis with ADPKD classified as 1C, 1D, or 1E according to Mayo classification
- Participants with the ability to communicate and use digital devices
- Participants with no severe visual impairment and cognitive dysfunction
You likely can't join if
- Participants who were previously exposured to tolvaptan
- Participants who are contraindicated to tolvaptan
- Participants who were judged ineligible by the investigator
The study team makes the final eligibility decision.
Where it's taking place
- Anyang-si, Gyeonggi-do, South Korea
- Seoul, Republic of Korea, South Korea
- Busan, South Korea
- Daegu, South Korea
- Gwangju, South Korea
- Seoul, South Korea
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Anyang-si, Gyeonggi-do, South Korea; Seoul, Republic of Korea, South Korea; Busan, South Korea; Daegu, South Korea; Gwangju, South Korea; Seoul, South Korea. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.